XXII: the cashflow

MyFinsight

For the quarter ending 2025-09-30, XXII had $1,763K increase in cash & cash equivalents over the period. -$4,024K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	5,489	-7,735
Impairment of long-lived assets - held for sale	0	293
Impairment of intangible assets	111	-
Amortization and depreciation	235	459
Amortization of right-of-use asset	70	136
Other non-cash gains	32	-
Provision for credit losses	-2	509
(gain) loss on sale or disposal of property, plant, and equipment	0	12
Debt related charges included in interest expense	602	984
Equity-based compensation	92	133
Change in fair value of warrant liabilities	33	174
Change in inventory reserves	27	-242
Accounts receivable	-551	1,852
Inventories	430	246
Prepaid expenses and other assets	-64	1,674
Insurance recoveries	9,500	-
Accounts payable	-406	-266
Accrued expenses	-44	1,056
Accrued payroll	-175	-3
Accrued excise taxes and fees	-457	1,818
Other liabilities	-246	14
Net cash used in operating activities	-4,018	-6,454
Acquisition of patents, trademarks, and licenses	16	59
Acquisition of property, plant and equipment	6	39
Proceeds from the sale of property, plant and equipment	0	770
Issuance of 2025 gvb promissory note	500	-
Net cash provided by (used in) investing activities	-522	672
Payments on notes payable	271	638
Proceeds from issuance of notes payable	0	1,023
Payments of penalties from long-term debt	28	-
Payments of long-term debt	3,291	1,017
Net proceeds from warrant exercise	0	5,075
Net proceeds from series a preferred stock	9,893	-
Net cash provided by financing activities	6,303	4,443
Net increase in cash and cash equivalents	1,763	-1,339
Cash and cash equivalents at beginning of period	4,422	-
Cash and cash equivalents at end of period	4,846	-

Unit: Thousand (K) dollars